Extended Paxlovid fails to ease long COVID symptoms in 959-person trial
Results from a clinical trial and published today in the journal Lancet Infectious Diseases show that the antiviral drug Paxlovid, commonly prescribed to treat acute COVID-19, does not affect long COVID symptoms compared with a placebo.
<p>Results from a clinical trial and published today in the journal Lancet Infectious Diseases show that the antiviral drug Paxlovid, commonly prescribed to treat acute COVID-19, does not affect long COVID symptoms compared with a placebo.</p>